Clinical DataREZPEG's therapeutic profile is viewed favorably as a novel mechanism of action.
Financial PerformanceNektar reported revenue of $11.2M and a net loss per share that was better than the consensus estimate, indicating financial performance exceeding expectations.
Market PotentialA large attractive opportunity is seen for REZPEG to emerge as a valuable addition to the treatment landscape as a novel, broader and importantly, safe mechanism.